Synthesis and Biological Evaluation of Manassantin Analogues for Hypoxia-Inducible Factor 1伪 Inhibition
详细信息 查看全文
- 作者：Do-Yeon Kwon ; Hye Eun Lee ; Douglas H. Weitzel ; Kyunghye Park ; Sun Hee Lee ; Chen-Ting Lee ; Tesia N. Stephenson ; Hyeri Park ; Michael C. Fitzgerald ; Jen-Tsan Chi ; Robert A. Mook ; Jr. ; Mark W. Dewhirst ; You Mie Lee ; Jiyong Hong
- 刊名：Journal of Medicinal Chemistry
- 出版年：2015
- 出版时间：October 8, 2015
- 年：2015
- 卷：58
- 期：19
- 页码：7659-7671
- 全文大小：635K
- ISSN：1520-4804
文摘
To cope with hypoxia, tumor cells have developed a number of adaptive mechanisms mediated by hypoxia-inducible factor 1 (HIF-1) to promote angiogenesis and cell survival. Due to significant roles of HIF-1 in the initiation, progression, metastasis, and resistance to treatment of most solid tumors, a considerable amount of effort has been made to identify HIF-1 inhibitors for treatment of cancer. Isolated from Saururus cernuus, manassantins A (1) and B (2) are potent inhibitors of HIF-1 activity. To define the structural requirements of manassantins for HIF-1 inhibition, we prepared and evaluated a series of manassantin analogues. Our SAR studies examined key regions of manassantin鈥檚 structure in order to understand the impact of these regions on biological activity and to define modifications that can lead to improved performance and drug-like properties. Our efforts identified several manassantin analogues with reduced structural complexity as potential lead compounds for further development. Analogues MA04, MA07, and MA11 down-regulated hypoxia-induced expression of the HIF-1伪 protein and reduced the levels of HIF-1 target genes, including cyclin-dependent kinase 6 (Cdk6) and vascular endothelial growth factor (VEGF). These findings provide an important framework to design potent and selective HIF-1伪 inhibitors, which is necessary to aid translation of manassantin-derived natural products to the clinic as novel therapeutics for cancers.